1401812-88-1

1401812-88-1 structure

Name: Lifastuzumab Vedotin
Chemical Name: Lifastuzumab Vedotin
CAS Number: 1401812-88-1
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cancer
Create Date: 2023-04-30 19:30:07
Modify Date: 2024-04-06 10:14:20
Lifastuzumab vedotin (DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research[1].

Name	Lifastuzumab Vedotin

Description	Lifastuzumab vedotin (DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research[1].
Related Catalog	Research Areas >> Cancer
References	[1]. S Banerjee, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 Apr 1;29(4):917-923. [2]. David E Gerber, et al. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. Clin Cancer Res. 2020 Jan 15;26(2):364-372.

No Any Chemical & Physical Properties